Voriconazole is a broad-spectrum triazole antifungal drug indicated in adults and children two years of age and older, for: Treatment of invasive aspergillosis. Treatment of candidemia in non-neutropenic patients. Treatment of severe invasive Candida infections (including C. krusei) resistant to fluconazole. Treatment of serious fungal infections due to Scedosporium spp. and Fusarium spp. Voriconazole should be administered primarily to patients with progressive infections that are potentially life-threatening. Prophylaxis of invasive fungal infections in high-risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Legal disclaimer: the content of this web site has been created exclusively for healthcare professionals in order to keep them informed and guide them in the proper use of medications. All texts referring to prescription products correspond to the guidelines approved by the corresponding authority in each country where Celnova Pharma operates. This content has no promotional purposes and is not intended to replace healthcare professional recommendations. Celnova Pharma always recommends to consult a qualified healthcare professional for any inquiry regarding to a particular medical condition.